載入...
Cost-effectiveness study of prophylaxis with emicizumab versus bypassing agents in patients with severe hemophilia A in Peru
Settings Hemophilia is a coagulation disorder that occurs in one in 5000 male births. Patients with untreated severe hemophilia A have hemorrhagic complications, including joint bleeds and decreased survival. Emicizumab is a monoclonal antibody approved by the United States for routine prophylaxis...
Na minha lista:
| Main Authors: | , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Medwave Estudios Limitada
2022-03-01
|
| 叢編: | Medwave |
| 主題: | |
| 在線閱讀: | https://www.medwave.cl/link.cgi/Medwave/Estudios/EvalEconom/8703.act |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|